Abstract:
PURPOSE: A composition containing an alcohol extract of Oligoporus tephroleucus is provided to suppress absorption of cholesterol in body, and to prevent or treat hyperlipidemia. CONSTITUTION: A composition for preventing or treating hyperlipidemia contains a C1-C10 alcohol extract of Oligoporus tephroleucus as an active ingredient. A pharmaceutical product for preventing or treating hyperlipidemia contains the alcohol extract as an active ingredient. A health functional food for preventing or treating hyperlipidemia contains the alcohol extract as an active ingredient. A method for preventing or treating hyperlipidemia comprises a step of administering the alcohol extract to animals exclusive of human. The alcohol extract suppresses absorption of cholesterol in blood and esterase activity. The alcohol extract is prepared by extracting Oligoporus tephroleucus with 90-99.9%(v/v) ethanol at 20-60 deg. C for 12-36 hours. [Reference numerals] (AA) CEL inhibition %; (BB) Water extract; (CC) Ethanol extract
Abstract:
PURPOSE: A composition containing a water extract of Tremella foliacea Fr. is provided to suppress digestion and absorption of fat in the body, and to prevent or treat obesity. CONSTITUTION: A composition for preventing or treating obesity contains a water extract of Tremella foliacea Fr. as an active ingredient. A pharmaceutical product for preventing or treating obesity contains the water extract as an active ingredient. A health functional food for preventing or treating obesity contains the water extract as an active ingredient. A method for preventing or treating obesity comprises a step of administering the water extract to animals exclusive of human. The water extract suppresses activity of pancreatic lipase. The water extract is prepared from Tremella foliacea Fr. with water at 20-60 deg. C for 12-36 hours. [Reference numerals] (AA) TGL activity inhibition(%); (BB) Water extract; (CC) (Comparative example) Ethanol extract
Abstract:
A method of regulating mammalian target-of-rapamycin(mTOR) activity based on mTOR control mechanism by phospholipase D(PLD) AND Rheb(Ras homolog enriched in brain) is provided to cure mTOR-related metabolic disease through the mTOR suppression. A method of regulating mammalian target-of-rapamycin(mTOR) activity comprises (i) coupling Rheb and mTOR through PLD2 by interaction between phospholipase D 2(PLD2) and Rheb; (ii) increasing the concentration of PA by moving phosphatidic acid(PA) produced from PLD2 to adjacent mTOR; and (iii) increasing mTOR kinase activity by coupling Rheb with mTOR through the increase of PA density around the adjacent mTOR.